AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
SEONGNAM, South Korea, March 20, 2025 /PRNewswire/ -- LISCure Biosciences Inc. ("LISCure") announced on the 2025 Feb that it has received approval from the Korean Ministry of Food and Drug Safety (KMFDS) for Mobiome®, a proprietary probiotic ingredient developed to promote hair health. Securing this regulatory approval from KMFDS highlights LISCure's strong research and development capabilities and technological expertise. This marks the world's first scientifically validated probiotic ingredient for hair health with plans for both domestic and global commercialization.
Mobiome®, developed using LISCure's proprietary technology, has demonstrated significant efficacy in preclinical models, enhancing antioxidant activity and exhibiting anti-inflammatory effects.
Mechanistic studies further confirmed its ability to stimulate follicular cell proliferation and regulate follicular cell cycles. In human clinical trials, Mobiome® showed statistically significant improvements in hair glossiness, elasticity, and overall user satisfaction (p<0.05, 95% confidence level) across multiple hair-related parameters, including texture, split ends, dryness, breakage, tangling, and damage.
Previously, hair care solutions were limited to pharmaceuticals and topical products such as shampoos. With this regulatory expansion, the hair health market is expected to experience significant growth both domestically and internationally.
According to global market research firm Research and Markets, the global hair growth supplement market is projected to grow at a compound annual growth rate (CAGR) of 14.7% from 2023 to 2030, reaching an estimated market value of $1.92 billion (approximately KRW 2.7 trillion) by 2030.
LISCure is actively developing functional ingredients targeting hair health, joint health, mental health, weight management, and kidney health, etc.
In parallel with its functional ingredient business, LISCure is accelerating its global pharmaceutical initiatives. The company has initiated patient dosing for LB-P8, a liver disease treatment that has received IND approval for Phase 2 clinical trials, as well as Orphan Drug designation and Fast Track designation in the U.S. Additionally, LISCure is advancing the joint commercialization of its brain shuttle platform, Exo-Pass N, in collaboration with global pharmaceutical partners. The company is also expediting the development of immuno-oncology therapies targeting colorectal and pancreatic cancers.
Leveraging the anticipated success of its global drug pipeline and growing revenue from functional ingredients, LISCure is preparing for an initial public offering (IPO). While prioritizing its core pharmaceutical R&D and technology licensing business, the company aims to establish a stable and sustainable revenue model through its functional health ingredient segment.
Hwa-Sup Chin, CEO of LISCure Biosciences, stated, "Securing the world's first regulatory approval for a hair health probiotic is a major milestone in our R&D efforts. By leveraging our proprietary platform technologies, we will continue expanding our pipeline beyond pharmaceuticals to include innovative functional health ingredients. Our strategy is to optimize the balance between therapeutics licensing deal with global big pharma and functional ingredient sales to strengthen our global competitiveness."
